This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS
by Megan Sanks
German dialysis provider Fresenius Medical Care (FMS) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. (NXTM) for $2 billion.
Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.
DexCom (DXCM) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
DexCom, Inc. (DXCM) was a big mover last session, as the company saw its shares rise nearly 7% on the day after the company reported better-than-expected third quarter, 2017 results.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Revenues Lag
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted strong numbers in the second quarter on growth in its Consulting Services, MWI Animal Health and World Courier businesses.
Fresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.
Masimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo's (MASI) stable performance across its businesses was the key highlight of second quarter.
Quality Systems (QSII) Beats on Q1 Earnings, Revenues
by Zacks Equity Research
Quality Systems (QSII) recorded stellar growth in its recurring revenue base in the first quarter. However, a downbeat guidance for adjusted earnings indicates looming concerns.
Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Despite registering strong growth at all the segments, unfavorable performances by Cardinal Health's (CAH) Branded products (including Cordis) offset sales, particularly at the Medical segment.
DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
DexCom (DXCM) recorded narrower-than-expected loss in the second quarter owing to robust growth in international space, particularly Germany.
Ecolab (ECL) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Ecolab Inc. (ECL) posted solid numbers in the second quarter owing to new business gains, better pricing, product innovation, and cost efficiencies.
Cerner (CERN) Misses Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Despite a stellar bookings growth rate, a downbeat guidance indicates looming concerns for Cerner (CERN). The Support and maintenance segment witnessed a lackluster performance in the second quarter
C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.
Integer (ITGR) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Integer's (ITGR) strong performance in the Cardio and Vascular business was a key highlight in second quarter 2017.
Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abiomed's (ABMD) strong Impella heart pump performance was a key highlight in first-quarter fiscal 2018.
Varian Medical (VAR) Tops Earnings & Lags Revenues in Q3
by Zacks Equity Research
Varian Medical's (VAR) solid performance in the Particle Therapy business and the launch of Halcyon radiotherapy treatment system were the key highlights of the third quarter.
Baxter (BAX) Beats on Q2 Earnings, Raises Long-Term Outlook
by Zacks Equity Research
Baxter International (BAX) delivered a solid second quarter driven by favorable tidings on the regulatory front, strategic partnerships and product launches.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
On Jul 11, we issued an updated research report on Bad Homburg, Germany-based Fresenius Medical Care (FMS), one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.
Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents
Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.
Fresenius (FMS) to Jointly Develop Acumen with Epic Systems
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA (FMS) announced that it would jointly develop Acumen 2.0 with Epic Systems Corporation.
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
by Zacks Equity Research
We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.
Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.